SOLLIEVO
Pharmaceuticals, INC.

EMERGENCY IN THE EMERGENCY DEPARTMENT

Sollievo Pharmaceuticals, Inc.

- Founded in 2018
- California C-corp
- Located in San Juan Capistrano

What we do

Through modification of existing drugs, we produce solutions to unmet medical needs.

The Team

Robert Schultz, Ph.D.
Founder and CEO

Dr. Schultz has held various Scientific and Executive Management positions during his 40-year career in the pharmaceutical and medical device industries. His expertise in the development of combination products and ability to lead internal and external resources in the start-up environment provides Sollievo with the leadership to successfully navigate the drug development process.

Paul Waymack, M.D., Sc.D.
Regulatory and Clinical

Dr. Waymack is a regulatory consultant, and previously worked as an FDA medical reviewer and special consulting reviewer, responsible for assessing new drug applications and investigational drug applications. Both his consulting and chief medical officer experience with early-stage companies will strengthen the management team in all activities pertaining to the development of Proviza, including regulatory and clinical activities.

Peter Schineller
Commercial Strategy Advisor

During his 35-year career, Mr. Schineller has held SVP and Chief Commercial Roles at leading drug and diagnostic companies and founded his own start-up Veras Pharmaceuticals., where he was the CCO. Mr. Schineller's role is to guide the company to a marketing and launch strategy that will ensure successful uptake of Proviza post-launch.

Steve King, BPharm
Business Development

Experienced Senior Manager with a 30-year history of working in the Pharmaceutical industry. Strong professional skills in Business Development, Alliance Management, Licensing, CMC Outsourcing, Biotechnology, Drug Development, and Pharmaceutical Project Management. Steve is responsible for identifying, sourcing, and contract negotiations with potential manufacturing partners and suppliers.

Problem: Violence in Healthcare is an Epidemic

- **Nearly 50% of emergency physicians and 70% of ER nurses report being assaulted injured**
- **25% of psychiatric nurses experience disabling injuries from patient assaults**

"Every minute these patients are agitated poses significant harm to both hospital staff and patients - *Dr. Becky Smith, Salisbury, N.C.*

MOST DANGEROUS WORKPLACE - ER nurses are 5X more likely to suffer patient-induced injuries compared to any other major industry and it's increasing

UNMET CLINICAL NEED -There have been no new drugs or delivery improvements of existing products in over 30 years that could mitigate the injury risk

VIOLENCE COST HOSPITALS $6 BILLION in 2016, motivating them to find ways to reduce attacks and turnover

NOT LIKE THE MOVIES - The onset of sedation for current products is extremely variable, 10 to 60 minutes,



Improving IM Sedation of Agitated and Violent Patients

Proviza Injection
(Avizafone dihydrochloride)





Proviza's Fast and Consistent Delivery of Avizafone Aims to Reduce Patient-to-Patient Sedation Variability



Reducing the variation in sedation time = Decreases injury risk to the ER staff

Faster and more reliable sedative – Why?

Because treating violent patients affects everyone

IT'S ALL HANDS ON DECK

- Requires multiple staff until the patient is calm
- Doctors' and nurses' attention is diverted away from other patients
- Results in longer wait times for new patients to see a doctor
- 60% of doctors surveyed say patients have left before receiving treatment
- The goal is to restore the regular ER routine as quickly as possible

Market Size

Two Addressable Markets: Acute Agitation and Seizure Emergencies



Global Market Growth Rate



Market Acceptance
Acute Agitation and Aggression



Percent of physicians likely to prescribe Proviza





Proviza is poised to take a significant share from the market leader - lorazepam

Current Status



Timeline to NDA Submission

SOLLIEVO Pharmaceuticals, INC.

Scale up to occur after results of the first clinical trial are known



Financial Projections

Forecast Assumptions:

- Launch in the US and top 3 EU Countries
- Low penetration in the seizure market
- Sales through distribution and marketing partner



Fundraising

Cost to Complete the First Clinical (PK-1)
Total Cost: $2.93 million



Milestone	Convertible Note	Series A	
Complete first clinical Study – 15 volunteers	**$3.25 M**		
Second Clinical & NDA Submission		**$5.0 M**	
Total to NDA Submission			**$8.2 M**

$3.25 million Convertible Note: Terms and Use of Funds

Use of Funds:

- **Process and formulation development**
- **Complete preclinical studies**
- **Submit Investigation New Drug application**
- **Legal and IP expenses**
- **Corporate expenses and salaries**

SECURITY
Convertible Note

INTEREST AND TERM
8% per annum
3-year Term

AUTOMATIC CONVERSION
Converts upon the closing of a Qualified Financing of a least $2 million

CONVERSION DISCOUNT
20% discount to the price/share of the Qualified Financing

SOLLIEVO
Pharmaceuticals, INC.

Proviza®

Improving Intramuscular Sedation in the Emergency Setting

Contact:

Robert K. Schultz, Ph.D.

schultz@sollievopharm.com

+1 858 243 0417